Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC

被引：2
|
作者：
Musick, K. [1 ]
Howard, J. [2 ]
Li, G. [3 ]
Vu, T. [4 ]
Korobko, D. [5 ]
Smilowski, M. [6 ]
Liu, L. [1 ]
Steeland, S. [1 ]
Noukens, J. [7 ]
Van Hoorick, B. [1 ]
Podhorna, J. [1 ]
Li, Y. [8 ]
Utsugisawa, K. [9 ]
Sacca, F. [10 ]
Wiendl, H. [11 ]
De Bleecker, J. [12 ]
Mantegazza, R. [13 ]
机构：
[1] Argenx, Ghent, Belgium
[2] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA
[3] Medsol Clin Res Ctr Inc, Port Charlotte, FL USA
[4] Univ S Florida, Dept Neurol, Morsani Coll Med, Tampa, FL USA
[5] State Novosibirsk Reg Clin Hosp, State Budgetary Healthcare Inst Novosibirsk Reg, Novosibirsk, Russia
[6] Med Univ Silesia, Dept Hematol & Bone Marrow Transplantat, Katowice, Poland
[7] Curare Consulting BV, Hamburg, Germany
[8] Cleveland Clin, Cleveland, OH USA
[9] Hanamaki Gen Hosp, Dept Neurol, Hanamaki, Japan
[10] Federico II Univ Naples, NRSO Dept, Naples, Italy
[11] Univ Munster, Dept Neurol, Munster, Germany
[12] Ghent Univ Hosp, Ghent, Belgium
[13] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuroimmunol & Neuromuscular Dis, Milan, Italy
来源：
NEUROMUSCULAR DISORDERS | 2023年 / 33卷
关键词：
D O I：
10.1016/j.nmd.2023.07.443
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P276
引用
收藏
页码：S179 / S179
页数：1
相关论文
共 50 条
  • [11] OBSERVED EFFICACY OF EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS ACROSS PATIENT SUBGROUPS IN THE ADAPT-SC plus STUDY
    Muppidi, Srikanth
    Vu, Tuan
    Bhavaraju-Sanka, Ratna
    Brauer, Eddie
    Kerstens, Rene
    Utsugisawa, Kimiaki
    Meisel, Andreas
    MUSCLE & NERVE, 2024, 70 (03) : 703 - 703
  • [12] LONG-TERM ASSESSMENT OF EFGARTIGIMOD IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS: ADAPT plus STUDY INTERIM RESULTS
    Jacob, Saiju
    Howard, James
    Bril, Vera
    Peric, Stojan
    De Bleecker, Jan
    T'joen, Carolin
    Travers, Jackalyne
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [13] COVID-19 VACCINATION RESPONSE IN PARTICIPANTS RECEIVING EFGARTIGIMOD IV OR EFGARTIGIMOD PH20 SC IN ADAPT plus OR ADAPT-SC
    Vu, Tuan
    Sacca, Francesco
    Howard, James F., Jr.
    Sleasman, John W.
    Gistelinck, Fien
    Duncombe, Paul
    Van Hoorick, Benjamin
    Steeland, Sophie
    Mantegazza, Renato
    De Bleecker, Jan L.
    Azar, Antoine
    Winthrop, Kevin
    MUSCLE & NERVE, 2024, 70 (03) : 611 - 611
  • [14] Long-term Safety and Efficacy of Efgartigimod in Patients With Generalised Myasthenia Gravis
    Meisel, A.
    Bril, V.
    Vu, T.
    Karam, C.
    Peric, S.
    De Bleecker, J.
    Murai, H.
    Beydoun, S.
    Pasnoor, M.
    Guglietta, A.
    Ulrichts, P.
    T'joen, C.
    Utsugisawa, K.
    Verschuuren, J.
    Mantegazza, R.
    Howard, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 62 - 62
  • [15] Long-Term Safety, Tolerability, And Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Concluding Analyses from the ADAPT plus Study
    Pasnoor, Mamatha
    Bril, Vera
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said
    Vu, Tuan
    Ulrichts, Peter
    Van Hoorick, Benjamin
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    Howard, James
    NEUROLOGY, 2023, 100 (17)
  • [16] Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: Concluding analyses from the ADAPT plus study
    Bril, Vera
    Pasnoor, Mamatha
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said
    Vu, Tuan
    Ulrichts, Peter
    Van Hoorick, Benjamin
    T'Joen, Caroline
    Kaprielian, Roger
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    Howard, James F., Jr.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [17] Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT plus study
    Ashcraft, E.
    Bril, V.
    Pasnoor, M.
    Karam, C.
    Peric, S.
    De Bleecker, J.
    Murai, H.
    Meisel, A.
    Beydoun, S.
    Vu, T.
    Ulrichts, P.
    Van Hoorick, B.
    T'joen, C.
    Utsugisawa, K.
    Verschuuren, J.
    Mantegazza, R.
    Howard, J.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S179 - S179
  • [18] Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
    Howard Jr, James F.
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said R.
    Pasnoor, Mamatha
    Guglietta, Antonio
    Van Hoorick, Benjamin
    Steeland, Sophie
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    FRONTIERS IN NEUROLOGY, 2024, 14
  • [19] THE EFFECT OF OBESITY IN EFFICACY AND SAFETY IN THE ADAPT TRIAL OF EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS
    Pulley, Michael
    Pasnoor, Mamatha
    Gelinas, Deborah
    Brauer, Edward
    Kerstens, Rene
    Beydoun, Said
    Howard, James
    MUSCLE & NERVE, 2022, 66 : S105 - S105
  • [20] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: phase 3 adapt study results
    Mantegazza, R.
    Bril, V.
    Vu, T.
    Karam, C.
    Peric, S.
    Margania, T.
    Murai, H.
    Biliska, M.
    Shakarishvili, R.
    Smilowski, M.
    Guglietta, A.
    Ulrichts, P.
    Vangeneugden, T.
    Utsugisawa, K.
    Verschuuren, J.
    Howard, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 80 - 80
12345